Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
Sign up free to see this.
Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.
No sentiment yet
Votes and Bull · Bear posts, 24h. At least 5 are needed.
How do you feel about ZBH?
Zacks Investment Research
Should Value Investors Buy Zimmer Biomet (ZBH) Stock?Zimmer Biomet (ZBH) is identified as an attractive value stock with a Zacks Rank #2 (Buy) rating and an 'A' Value grade. The company trades at a P/E ratio of 11.98, below its industry average of 15.93, and demonstrates solid valuation metrics across P/B and P/CF ratios, suggesting it may be undervalued relative to its earnings outlook.
Zacks Investment Research
Zimmer Biomet (ZBH) is a Top-Ranked Value Stock: Should You Buy?Zimmer Biomet (ZBH), a musculoskeletal healthcare company, has been identified as a #2 (Buy) on the Zacks Rank with a VGM Score of B and Value Style Score of A. The company features attractive valuation metrics with a forward P/E ratio of 10.51, and analysts have revised earnings estimates higher, with the consensus estimate at $8.54 per share and an average earnings surprise of +4.5%.
Zacks Investment Research
Are Investors Undervaluing Baxter International (BAX) Right Now?Zacks highlights two Medical-Products stocks with strong value characteristics: Baxter International (BAX) and Zimmer Biomet (ZBH), both holding Zacks Rank #2 (Buy) ratings and Value grade A. Both stocks trade at attractive valuations compared to industry averages across multiple metrics including P/E, PEG, P/B, and P/S ratios, suggesting they are currently undervalued with strong earnings outlooks.
Headlines open the publisher's site.
No threads yet
Community opinions, not advice. Posts with a target get a receipt. How receipts work ›
